

1 **Asymptomatic and mildly symptomatic influenza virus infections by season --**  
2 **Case-ascertained household transmission studies, United States, 2017-2023**

3 Jessica E. Biddle<sup>1</sup>, Huong Q. Nguyen<sup>2</sup>, H. Keipp Talbot<sup>3</sup>, Melissa A. Rolfes<sup>1</sup>, Matthew  
4 Biggerstaff<sup>1</sup>, Sheroi Johnson<sup>1</sup>, Carrie Reed<sup>1</sup>, Edward A. Belongia<sup>2</sup>, Carlos G. Grijalva<sup>3</sup>,  
5 Alexandra M. Mellis<sup>1</sup>

6  
7 <sup>1</sup> Centers for Disease Control and Prevention, Atlanta, Georgia

8 <sup>2</sup> Marshfield Clinic Research Institute, Marshfield, Wisconsin

9 <sup>3</sup> Vanderbilt University Medical Center, Nashville, Tennessee

10

11

12

13 **Acknowledgements:** The authors would like to thank Alicia Fry, Scott Blackwell, Emma  
14 Pedigree Cannon, Holly Morse, Megan Eluhu, Emily Jookar, Christina Khouri, Robert  
15 Lyons, Carleigh Frazier, Janika Raynes, Preston Gibson, Karen Malone, Sarah Davis,  
16 Olivia Doak, Judy King, Dayna Wyatt, and the study participants.

17

18 **Financial Support:** These research studies were supported by CDC (grant  
19 5U01IP001078 awarded to the Marshfield Clinic Research Institute, grant  
20 5U01IP001083 awarded to Vanderbilt University Medical Center) and contract  
21 75D30121C11656 jointly funded by the CDC and the US Food and Drug Administration  
22 and awarded to Vanderbilt University Medical Center).

23

24 The Vanderbilt Institute for Clinical and Translational Research (VICTR) is funded by  
25 the National Center for Advancing Translational Sciences (NCATS) Clinical  
26 Translational Science Award (CTSA) Program, Award Number 5UL1TR002243-03. The  
27 content is solely the responsibility of the authors and does not necessarily represent the  
28 official views of the NIH.

29

30 **Competing Interest Statement:** EAB receives research support from CSL Seqirus  
31 unrelated to the current work. HQN receives research support unrelated to this work  
32 from CSL Seqirus, GSK, ModernaTX Inc, and honorarium for participating in a  
33 consultancy group for Moderna outside the submitted work.

34 Dr. Grijalva has received consulting fees from Merck, and research support from  
35 SyneosHealth, NIH, FDA and AHRQ.

36

37 **Disclaimer:** The findings and conclusions in this report are those of the authors and do  
38 not necessarily represent the official position of the US Centers for Disease Control and  
39 Prevention.

40

41

42

43

## 44 **Abstract**

45 Asymptomatic influenza virus infection occurs but may vary by factors such as age,  
46 influenza vaccination status, or influenza season. We examined the frequency of  
47 influenza virus infection and associated symptoms using data from two case-  
48 ascertained household transmission studies (conducted from 2017—2023) with  
49 prospective, systematic collection of respiratory specimens and symptoms. From the  
50 426 influenza virus infected household contacts that met our inclusion criteria, 8% were  
51 asymptomatic, 6% had non-respiratory symptoms, 23% had acute respiratory  
52 symptoms, and 62% had influenza-like illness symptoms. Understanding the prevalence  
53 of asymptomatic and mildly symptomatic influenza cases is important for implementing  
54 effective influenza prevention strategies and enhancing the effectiveness of symptom-  
55 based surveillance systems.

## 56 **Introduction**

57 Influenza virus infections cause a range of health outcomes, spanning from  
58 asymptomatic infection to severe illness including hospitalizations and death. The  
59 COVID-19 pandemic has underscored the significance of asymptomatic transmission of  
60 respiratory pathogens, prompting further research to understand the frequency of  
61 asymptomatic infection with influenza virus and its implications on transmission.  
62 However, studying asymptomatic and mildly symptomatic influenza virus infections is  
63 challenging because of the need for prospective and active follow-up [1]. Even with  
64 prospective follow-up, estimates of the asymptomatic fraction have been  
65 heterogeneous, varying by experimental setting, study design, and case definitions for  
66 describing infections as asymptomatic [2-6].

67           The occurrence of asymptomatic influenza virus infection may also vary by age,  
68 vaccination status, and infecting virus type and subtype, but this heterogeneity is not  
69 well described. Understanding how these factors can influence asymptomatic influenza  
70 is crucial for developing effective public health strategies, as they can significantly  
71 impact the transmission dynamics and overall burden of influenza in populations. The  
72 objective of this analysis was to examine the proportion of asymptomatic influenza virus  
73 infections among household contacts and explore the asymptomatic fraction by  
74 individual-level factors using recent case-ascertained household studies of influenza  
75 that systematically collected daily respiratory specimens and symptoms.

## 76 **Methods**

77           Two case-ascertained household transmission studies were conducted in  
78 Tennessee and Wisconsin across five influenza seasons from 2017–2023. Index cases  
79 with laboratory-confirmed influenza virus infection were enrolled within 7 days of  
80 symptom onset. At enrollment, all participants self-reported demographics, household  
81 characteristics, medical history, symptoms in the week prior to enrollment, and influenza  
82 vaccine receipt for the current season. Both index cases and their household contacts  
83 were eligible to enroll. Household contacts were defined as those who (1) slept in the  
84 same household as the index case for at least half the preceding month, (2) who were  
85 present for at least one night in the week before enrollment, and (3) planned to continue  
86 residing in the household during the follow-up period. Enrolled household members had  
87 nasal swabs collected daily, for 5 days (2017-2020 in Wisconsin), 7 days (2017-2020 in  
88 Tennessee), or 10 days (2021-2023 at both sites). During these sampling periods,  
89 participants also completed symptom diaries daily. Nasal swabs were tested for

90 influenza viruses using reverse transcriptase polymerase chain reaction (RT-qPCR).  
91 Influenza positive specimens were subtyped according to methods previously  
92 described<sup>22</sup>. Participants reported presence or absence of the following signs and  
93 symptoms: fever, cough, runny nose, nasal congestion, fatigue, wheezing, shortness of  
94 breath, and sore throat on each daily symptom diary. Protocols and procedures were  
95 reviewed and approved by the institutional review boards (IRB) at the Marshfield Clinic  
96 Research Institute and Vanderbilt University from 2017-2020 and a single IRB at  
97 Vanderbilt University from 2021-2023.

98         Analyses were restricted to household contacts who tested positive for influenza.  
99 Contacts were excluded if they had less than 3 lab results or daily diaries, or if their first  
100 specimen was taken more than 7 days from the index's onset date. Analyses were also  
101 restricted to up to 7 days of follow-up. As a sensitivity analysis, we also restricted to 5  
102 days of follow-up, which was the minimum duration of symptom surveillance collected at  
103 any site during any season. For analyses, we used data from all available daily diaries  
104 and implemented 3 definitions to classify the infection: (1) asymptomatic vs  
105 symptomatic, (2) without acute respiratory illness (ARI) vs with ARI, and (3) without  
106 influenza-like illness (ILI) vs with ILI. Being symptomatic was defined as having at least  
107 one of the following signs or symptoms: fever, cough, runny nose, nasal congestion,  
108 fatigue, wheezing, shortness of breath, or sore throat. ARI was defined as having two or  
109 more of the following signs or symptoms: fever, cough, runny nose, nasal congestion, or  
110 sore throat [8]. ILI was defined as having fever and cough or fever and sore throat. For  
111 descriptive purposes, participants were classified into 4 mutually exclusive groups: (1)  
112 asymptomatic overall, (2) symptomatic, non-ARI, (3) ARI but not ILI, and (4) ILI.

113 Three multivariable, robust logistic regression models were conducted for each  
114 symptom definition to estimate the proportion of influenza positive household contacts  
115 who were asymptomatic, did not develop ARI, and did not develop ILI. All regression  
116 models accounted for household clustering. Each of the three regression models were  
117 further stratified by age group, by season, and by vaccination status. Regression  
118 models stratified by age group were adjusted for season and vaccination status.  
119 Regression models stratified by season were adjusted for age group and vaccination  
120 status. And finally, regression models stratified by vaccination status were adjusted for  
121 age group and season. These regression models were used to generate predicted  
122 probabilities of the fraction of infected contacts with each symptom presentation, which  
123 are presented by age, by season, and by vaccination status.

## 124 **Results**

125 Four hundred and twenty-six household contacts tested positive for influenza and  
126 met our criteria for inclusion. Fifty-four percent of included contacts were from  
127 Tennessee, 50% were male, 49% were aged <18 years, 73% were white, non-Hispanic,  
128 and 60% were unvaccinated against influenza during the season they were enrolled  
129 (Supplemental Table 1). Influenza viruses detected in the infected contacts varied by  
130 season (Supplemental Table 1).

131 From the 426 infected household contacts, 36 (8%) were asymptomatic, 27 (6%)  
132 had symptoms but not-ARI, 98 (23%) had ARI but not ILI, and 265 (62%) had ILI during  
133 the follow-up period (Figure 1). The proportion of asymptomatic or mildly symptomatic  
134 (without ARI) contacts was highest among adult participants (ages  $\geq 18$  years) and those  
135 who were vaccinated (Figure 1). Additionally, the proportion of asymptomatic or mildly

136 symptomatic contacts was highest in seasons after the COVID-19 pandemic started  
137 compared to the pre-pandemic seasons (Figure 1).

138         We completed three robust multivariable logistic regression models accounting  
139 for age, season, and vaccination against each binary case definition for asymptomatic  
140 and mildly symptomatic infections. The prevalence of asymptomatic infections across  
141 age groups varied: 8% for ages 0–17, 12% for ages 18–49, and 5% for ages ≥50 years.  
142 Similarly, absence of ARI was observed in 16% of contacts for ages 0–17, 17% for ages  
143 18–49, and 13% for ages ≥50 years, while absence of ILI occurred in 30% for ages 0–  
144 17, 54% for ages 18–49, and 48% for ages ≥50 years (Table 1). Notably, the  
145 prevalence of asymptomatic infections was highest in the 2021-2022 and 2022-2023  
146 seasons compared to pre-pandemic seasons. Additionally, adjusting for age group and  
147 season, 12% of vaccinated contacts and 5% of unvaccinated contacts were  
148 asymptomatic. Vaccinated contacts also showed lower percentages of ARI (9% vs 25%)  
149 and ILI (36% vs. 52%) compared to unvaccinated contacts (Table 1). Trends by age  
150 group, season, and vaccination status remained the same when assessments were  
151 restricted to the first 5 days of follow-up (Supplemental Table 2).

## 152 **Discussion**

153         In this study, the proportion of asymptomatic infection among individuals with  
154 laboratory-confirmed influenza was 8% overall. Mildly symptomatic infections,  
155 characterized by the absence of ARI, accounted for 6% of cases, while mildly  
156 symptomatic infections, characterized by the presence of ARI but not ILI, comprised  
157 23% of cases. Consistent with previous studies, we found that asymptomatic influenza  
158 virus infections occur and further show that the asymptomatic fraction, as we estimated

159 using a household transmission study, varies by season and, possibly, influenza  
160 vaccination.

161           Understanding the fraction of individuals with influenza who are asymptomatic or  
162 have only mild symptoms has implications for both the prevention of influenza through  
163 transmission control and the ability to detect influenza through symptom-based  
164 surveillance systems, particularly as these infections may be more common than  
165 previously thought, underscoring the significance of our updated evidence. As  
166 highlighted by a review by Montgomery et al., if a significant proportion of influenza  
167 transmission occurs through individuals with mild or no symptoms, prevention strategies  
168 beyond symptom-based case identification, such as vaccination, gain heightened  
169 importance [1]. In addition, if the fraction of individuals who meet standard case  
170 definitions for influenza changes over time or varies age groups, this has implications  
171 for continued ability to detect influenza or estimate total illnesses or infections.

172           The present study showed a trend of increased asymptomatic and mildly  
173 symptomatic influenza virus infections during the post COVID-19 pandemic seasons.  
174 Following historically low levels of influenza activity in 2020, which persisted into 2021  
175 [9], there was an increase in the risk of influenza virus infection among household  
176 contacts in the 2021-2022 season compared to pre-pandemic seasons [7]. Further  
177 research is needed to understand the factors that are driving the increase in infections  
178 post-pandemic. We hypothesize the increase in infections could be due to increased  
179 susceptibility among individuals without recent exposure. We further see that during the  
180 2021-2022 season, influenza virus infections in this study may have been more mild or  
181 were asymptomatic.

182 Previous studies have examined asymptomatic fraction by age and vaccination  
183 status. Consistent with our findings, previous research has shown asymptomatic  
184 influenza virus infection among children is less common compared to adults [10].  
185 Findings from the household cohort study out of South Africa further underscores this  
186 age-related pattern, showing that the rates of influenza virus infection and symptomatic  
187 illnesses were highest in children <5 years and decreased with increasing age [3].  
188 Studies exploring the association of influenza vaccination and asymptomatic fractions  
189 within households are lacking. However, one previous study examining the protective  
190 effect of influenza vaccination against symptomatic infection in healthcare workers  
191 demonstrated that vaccinated health care workers had a higher proportion of  
192 asymptomatic influenza virus infection compared to unvaccinated health care workers  
193 which is consistent with our present findings [11]. Further research with larger sample  
194 sizes should explore the association between vaccination status and progression of  
195 symptoms.

196 There are several limitations to our study. First, our study recruited index cases  
197 who sought medical care for their illness. Thus, our analysis would not have included  
198 household contacts exposed to index cases with milder or asymptomatic presentations  
199 that would likely have not sought medical care. Second, serological data, which have  
200 been previously used to generate estimates of asymptomatic infections, were not  
201 included in this study and therefore we cannot supplement the ascertainment of  
202 asymptomatic cases with those data. Additionally, we were unable to stratify data into  
203 finer-resolved age groups or influenza types/subtypes due to sample size constraints  
204 across seasons, limiting the ability to discern more age or influenza-type specific



205 patterns of asymptomatic or mildly symptomatic infections. This analysis was restricted  
206 to 7 days of active follow-up (median of 9 days of follow up after first illness in the  
207 household) and some individuals who were classified as asymptomatic may have  
208 developed symptoms later. Finally, we collected data exclusively from households in  
209 two US states and therefore our results may not be generalizable to broader  
210 populations. Looking forward, future research efforts should consider inclusion of more  
211 diverse demographic and geographic settings to ensure a comprehensive  
212 understanding of asymptomatic influenza virus infections.

213         These results underscore the value of household transmission studies with close  
214 follow-up of exposed household members to better understand the spectrum of  
215 symptoms seen in influenza virus infection, including the rate of asymptomatic infection  
216 among individuals with influenza.

217

218

219

220

221

222

223

224

## 225   **References**

- 226   1.     Montgomery, M.P., et al., *The role of asymptomatic infections in influenza transmission: what do*  
227         *we really know*. The Lancet Infectious Diseases.
- 228   2.     Tsang, T.K., et al., *Reconstructing household transmission dynamics to estimate the*  
229         *infectiousness of asymptomatic influenza virus infections*. Proceedings of the National Academy  
230         of Sciences, 2023. **120**(33): p. e2304750120.
- 231   3.     Cohen, C., et al., *Asymptomatic transmission and high community burden of seasonal influenza*  
232         *in an urban and a rural community in South Africa, 2017&#x2013;18 (PHIRST): a population*  
233         *cohort study*. The Lancet Global Health, 2021. **9**(6): p. e863-e874.
- 234   4.     Hayward, A.C., et al., *Comparative community burden and severity of seasonal and pandemic*  
235         *influenza: results of the Flu Watch cohort study*. Lancet Respir Med, 2014. **2**(6): p. 445-54.
- 236   5.     Leung, N.H., et al., *Review Article: The Fraction of Influenza Virus Infections That Are*  
237         *Asymptomatic: A Systematic Review and Meta-analysis*. Epidemiology, 2015. **26**(6): p. 862-72.
- 238   6.     Furuya-Kanamori, L., et al., *Heterogeneous and Dynamic Prevalence of Asymptomatic Influenza*  
239         *Virus Infections*. Emerg Infect Dis, 2016. **22**(6): p. 1052-6.
- 240   7.     Rolfes, M.A., et al., *Household Transmission of Influenza A Viruses in 2021-2022*. JAMA, 2023.  
241         **329**(6): p. 482-489.
- 242   8.     *Glossary of Influenza (Flu) Terms*. 2024; Available from:  
243         <https://www.cdc.gov/flu/about/glossary.htm>.
- 244   9.     Olsen, S.J., et al., *Changes in Influenza and Other Respiratory Virus Activity During the COVID-19*  
245         *Pandemic - United States, 2020-2021*. MMWR Morb Mortal Wkly Rep, 2021. **70**(29): p. 1013-  
246         1019.
- 247   10.    Hoy, G., et al., *The Spectrum of Influenza in Children*. Clin Infect Dis, 2023. **76**(3): p. e1012-e1020.
- 248   11.    Bénet, T., et al., *Incidence of Asymptomatic and Symptomatic Influenza Among Healthcare*  
249         *Workers: A Multicenter Prospective Cohort Study*. Clinical Infectious Diseases, 2020. **72**(9): p.  
250         e311-e318.

251

252

253

254

255

256

257

258


259

260

261

262

263 Figure 1. Symptom status of influenza positive contacts by age group, season, and vaccination  
 264 status, United States, 2017 - 2023



265 Symptomatic Status ■ ILI Symptoms ■ ARI Symptoms ■ Non-ARI Symptoms ■ Asymptomatic

266 Symptomatic status was defined using the following symptom definitions (1) **Influenza-like Illness (ILI)**  
 267 **Symptoms:** Fever + (Cough OR Sore Throat), (2) **Acute Respiratory Illness (ARI) Symptoms:** 2 or  
 268 more of the following symptoms: Fever, Cough, Runny Nose, Nasal Congestion, Sore Throat, and (3)  
 269 **Non-ARI Symptoms:** At least one of the following symptoms: Fever, Cough, Runny Nose, Nasal  
 270 Congestion, Fatigue, Wheezing, Shortness of Breath, Sore Throat. From the 426 included infected  
 271 household contacts 36 (8%) were completely asymptomatic, 27 (6%) had non-ARI symptoms, 98 (23%)  
 272 had ARI symptoms and 265 (62%) had ILI symptoms.

273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284

285 Table 1. Characteristics of the cohort & frequencies of asymptomatic infections, United States,  
 286 2017-2023

	Influenza positive contacts	Asymptomatic influenza positive contacts	Modeled Asymptomatic Infections*	Contacts without ARI	Modeled Infections without ARI*	Contacts without ILI	Modeled Infections without ILI*
	<b>N</b>	<b>N</b>	<b>% (CI)</b>	<b>N</b>	<b>% (CI)</b>	<b>N</b>	<b>% (CI)</b>
<b>Age Group</b>							
0 – 17 years	208	13	8 (4-14)	26	16 (11-24)	53	30 (23-39)
18 – 49 years	161	19	12 (7-20)	27	17 (11-26)	80	54 (44-63)
50+ years	57	4	5 (2-15)	10	13 (7 – 23)	28	48 (35-61)
<b>Season</b>							
2017 – 2018	45	5	10 (4-23)	7	15 (7-29)	17	38 (24-55)
2018 – 2019	107	5	4 (2- 9)	11	8 (4-16)	34	34 (24-45)
2019 – 2020	152	5	3 (1-9)	8	5 (2-11)	44	34 (26-43)
2021 – 2022	45	7	15 (7-30)	16	36 (21-53)	26	59 (40-75)
2022 – 2023	77	14	17 (9-31)	21	30 (18-46)	40	55 (42-68)
<b>Influenza Vaccination Status</b>							
Vaccinated	169	19	12 (8-18)	37	25 (17-34)	77	52 (42-61)
Unvaccinated	257	17	5 (3-10)	26	9 (6-14)	84	36 (29-44)

287 \*A robust logistic regression model accounting for household clustering was conducted to estimate the  
 288 proportion of influenza positive household contacts that were asymptomatic, without ARI, and without ILI.  
 289 Adjusted marginal estimates and 95% confidence intervals are shown as percentages. Age group was  
 290 adjusted for season and vaccination status. Season was adjusted for age group and vaccination status.  
 291 Vaccination status was adjusted for age group and season.

292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303

304 Supplemental Table 1. Characteristics of influenza positive contacts by season, United States,  
305 2017-2023

<b>Characteristic</b>	<b>Overall, N = 426<sup>1</sup></b>	<b>2017-2018, N = 45<sup>1</sup></b>	<b>2018-2019, N = 107<sup>1</sup></b>	<b>2019-2020, N = 152<sup>1</sup></b>	<b>2021-2022, N = 45<sup>1</sup></b>	<b>2022-2023, N = 77<sup>1</sup></b>
<b>State</b>						
TN	231 (54%)	24 (53%)	47 (44%)	46 (30%)	45 (100%)	69 (90%)
WI	195 (46%)	21 (47%)	60 (56%)	106 (70%)	0 (0%)	8 (10%)
<b>Sex</b>						
Female	214 (50%)	26 (58%)	52 (49%)	69 (45%)	29 (64%)	38 (49%)
Male	212 (50%)	19 (42%)	55 (51%)	83 (55%)	16 (36%)	39 (51%)
<b>Race, Ethnicity</b>						
Asian, Non-Hispanic	11 (2.6%)	0 (0%)	3 (2.8%)	8 (5.3%)	0 (0%)	0 (0%)
Black, Non-Hispanic	20 (4.7%)	2 (4.4%)	4 (3.7%)	6 (3.9%)	7 (16%)	1 (1.3%)
Hispanic/Latino	69 (16%)	6 (13%)	12 (11%)	13 (8.6%)	16 (36%)	22 (29%)
Multiple race, Non-Hispanic	9 (2.1%)	0 (0%)	1 (0.9%)	6 (3.9%)	2 (4.4%)	0 (0%)
NH/OPI, Non-Hispanic	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (1.3%)
Unknown/Refused	3 (0.7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (3.9%)
White, Non-Hispanic	313 (73%)	37 (82%)	87 (81%)	119 (78%)	20 (44%)	50 (65%)
<b>Vaccination Status</b>						
Unvaccinated	257 (60%)	26 (58%)	50 (47%)	100 (66%)	25 (56%)	56 (73%)
Vaccinated	169 (40%)	19 (42%)	57 (53%)	52 (34%)	20 (44%)	21 (27%)
<b>Age Group</b>						
0-17	208 (49%)	16 (36%)	60 (56%)	90 (59%)	15 (33%)	27 (35%)
18-49	161 (38%)	19 (42%)	33 (31%)	50 (33%)	18 (40%)	41 (53%)
50+	57 (13%)	10 (22%)	14 (13%)	12 (7.9%)	12 (27%)	9 (12%)
<b>Flu Type</b>						
A, H1	152 (36%)	8 (18%)	41 (38%)	87 (57%)	2 (4.4%)	14 (18%)
A, H3	139 (33%)	24 (53%)	61 (57%)	0 (0%)	29 (64%)	25 (32%)
A, no subtyping	44 (10%)	1 (2.2%)	3 (2.8%)	1 (0.7%)	14 (31%)	25 (32%)
B, no subtyping	82 (19%)	11 (24%)	1 (0.9%)	62 (41%)	0 (0%)	8 (10%)
Unknown	9 (2.1%)	1 (2.2%)	1 (0.9%)	2 (1.3%)	0 (0%)	5 (6.5%)

<sup>1</sup>n (%)

307 Supplemental Table 2. Characteristics of the cohort & frequencies of asymptomatic infections  
 308 with follow-up restricted to 5 days<sup>+</sup>, United States, 2017-2023

	Influenza positive contacts	Asymptomatic influenza positive contacts	Modeled Asymptomatic infections*	Contacts without ARI	Modeled Infections without ARI*	Contacts without ILI	Modeled Infections without ILI*
	<b>N</b>	<b>N</b>	<b>% (CI)</b>	<b>N</b>	<b>% (CI)</b>	<b>N</b>	<b>% (CI)</b>
<b>Age Group</b>							
0 – 17 years	204	11	7 (3-12)	24	15 (9-22)	51	29 (22-38)
18 – 49 years	159	19	12 (7-20)	27	17 (11-26)	79	53 (44-62)
50+ years	57	4	5 (2-15)	10	13 (7-23)	28	48 (35-61)
<b>Season</b>							
2017 – 2018	42	3	6 (2-18)	5	11 (5-25)	15	35 (21-52)
2018 – 2019	106	5	4 (2-9)	11	9 (4-17)	34	34 (25-45)
2019 – 2020	150	5	3 (1-9)	8	5 (2-12)	43	34 (25-43)
2021 – 2022	45	7	15 (7-30)	16	36 (22-53)	26	59 (40-75)
2022 – 2023	77	14	17 (9-31)	21	30 (18-46)	40	55 (41-67)
<b>Influenza Vaccination Status</b>							
Vaccinated	167	18	11 (7-17)	36	24 (17-33)	75	51 (41-60)
Unvaccinated	253	16	5 (3-9)	25	9 (6-14)	83	36 (29-44)

309 \*A robust logistic regression model accounting for household clustering was conducted to estimate the  
 310 proportion of influenza positive household contacts that were asymptomatic, without ARI, and without ILI.  
 311 Adjusted marginal estimates and 95% confidence intervals are shown as percentages. Age group was  
 312 adjusted for season and vaccination status. Season was adjusted for age group and vaccination status.  
 313 Vaccination status was adjusted for age group and season.

314 <sup>+</sup>Follow-up was restricted to 5 days of follow-up which was the minimum collected per site protocol as  
 315 sensitivity analyses.

316